Drug Profile
TAS 0313
Alternative Names: TAS-0313Latest Information Update: 21 Oct 2022
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics; Peptide vaccines
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Urogenital cancer
- Phase I/II Solid tumours
Most Recent Events
- 21 Oct 2022 Taiho Pharmaceutical suspends a phase-I/II clinical trials for Solid tumours in Japan
- 26 Jul 2022 TAS 0313 is still in phase II trials for urogenital cancer in Japan (Taiho Pharmaceuticals pipeline, July 2022)
- 04 Jun 2021 Efficacy and safety data from a phase I/II trial in Solid tumours presented at the American Society of Clinical Oncology (ASCO-2021)